Lei Yang

Title: Lei Yang: Innovator in Chimeric Antigen Receptors

Introduction

Lei Yang is a prominent inventor based in Anhui, China. He has made significant contributions to the field of biotechnology, particularly in the development of chimeric antigen receptors (CARs) for cancer treatment. With a total of seven patents to his name, Yang's work is at the forefront of innovative cancer therapies.

Latest Patents

Among his latest patents is a groundbreaking application titled "Chimeric antigen receptors targeting BCMA and methods of use thereof." This patent provides single-domain antibodies targeting BCMA and describes chimeric antigen receptors, including monovalent CAR and multivalent CAR, which comprise one or more anti-BCMA single-domain antibodies. The application also details engineered immune effector cells, such as T cells, that incorporate these chimeric antigen receptors. Additionally, it includes pharmaceutical compositions, kits, and methods for treating cancer. Another notable patent is "Chimeric antibody immune effector cell engagers and methods of use thereof." This invention features a chimeric antibody immune cell engager that includes a target cell binding domain and an immune effector cell binding domain, along with associated pharmaceutical compositions, kits, and treatment methods.

Career Highlights

Throughout his career, Lei Yang has worked with leading companies in the biotechnology sector. He has been associated with Legend Biotech USA Inc. and Nanjing Legend Biotech Co., Ltd., where he has contributed to the advancement of innovative cancer therapies. His expertise in the field has positioned him as a key player in the development of cutting-edge treatments.

Collaborations

Lei Yang has collaborated with notable colleagues, including Xiaohu Fan and Qiuchuan Zhuang, who have contributed to his research and development efforts. These collaborations have further enhanced the impact of his work in the biotechnology field.

Conclusion

In summary, Lei Yang is a distinguished inventor whose work in chimeric antigen receptors is paving the way for new cancer treatments. His innovative patents and collaborations highlight his commitment to advancing biotechnology and improving patient outcomes.